Novelty Stress Increases Fecal Pellet Output in Mongolian Gerbils : Effects of Several Drugs
スポンサーリンク
概要
- 論文の詳細を見る
Stress-induced colonic functional changes have been investigated mainly under conditions involving physical stress, like in the restraint stress model. In this study, we established a new stress-induced defecation model involving the placement of Mongolian gerbils in a novel environment (novelty stress) and determined the effects of several drugs on novelty stress-induced fecal pellet output. When animals kept in groups were placed individually in small cages, the fecal pellet output markedly increased, although the upper intestinal transit measured by charcoal method was not changed. The concentration of plasma adrenocorticotropic hormone was moderately but significantly increased by the novelty stress. Drugs reportedly effective for stress-induced defecation, like alosetron hydrochloride, atropine sulfate, and trimebutine maleate, inhibited both the novelty stress-induced increase in fecal pellet output and spontaneous defecation. In contrast, TAK-637, a tachykinin NK1-receptor antagonist, and diazepam inhibited the novelty stress induced defecation but did not inhibit spontaneous defecation. The present study indicated that novelty stress increases fecal pellet output without affecting the upper intestinal transit; this model may be useful for evaluating the effects of drugs on stress-stimulated colonic motility.
- 社団法人 日本薬理学会の論文
- 2005-08-20
著者
-
Inatomi Nobuhiro
Pharmaceutical Research Division Takeda Chemical Industries Ltd.
-
Inatomi Nobuhiro
Pharmacology Research Laboratories I Pharmaceutical Research Division Takeda Pharmaceutical Company
-
Nagaya Hideaki
Pharmacology Research Laboratories I Pharmaceutical Research Division Takeda Pharmaceutical Company
-
Nagaya Hideaki
Pharmaceutical Research Division Takeda Chemical Industries Ltd.
-
OKANO Shiho
Pharmacology Research Laboratories I, Pharmaceutical Research Division, Takeda Pharmaceutical Compan
-
Okano Shiho
Pharmacology Research Laboratories I Pharmaceutical Research Division Takeda Pharmaceutical Company
-
Inatomi Nobuhiro
Pharmaceutical Res. Div. Takeda Pharmaceutical Co. Ltd. Jpn
関連論文
- Role of Endogenous Basic Fibroblast Growth Factor in the Healing of Gastric Ulcers in Rats
- Microbial Conversion of EM574 and EM523, Gastrointestinal motor Stimulating Agents
- Bioactive Metabolites of EM574 and EM523, Erythromycin Derivatives Having Strong Gastrointestinal Motor Stimulating Activity
- Vagus-Dependent and Vagus-Independent Mechanisms of Action of the Erythromycin Derivative EM574 and Motilin in Dogs
- Synthesis of Eosinophil Infiltration Inhibitors with Antihistaminic Activity
- Novelty Stress Increases Fecal Pellet Output in Mongolian Gerbils : Effects of Several Drugs
- Establishment and Validation of a Rabbit Model for In Vivo Pharmacodynamic Screening of Tachykinin NK_2 Antagonists
- Effects of TAK-480, a Novel Tachykinin NK2–Receptor Antagonist, on Visceral Hypersensitivity in Rabbits and Ricinoleic Acid–Induced Defecation in Guinea Pigs
- Effects of TAK-480, a Novel Tachykinin NK_2-Receptor Antagonist, on Visceral Hypersensitivity in Rabbits and Ricinoleic Acid-Induced Defecation in Guinea Pigs
- Comparison of the Motor-Stimulating Action of EM523, an Erythromycin Derivative, and Prostaglandin F2.ALPHA. in Conscious Dogs.